TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive~* Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method~* Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period~* Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1~* Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \[AED\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED~Exclusion Criteria:~* Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline~* Subject is currently treated with levetiracetam~* Subject has taken levetiracetam within 90 days prior to Visit 1

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BRV 200 mg/day (Type: EXPERIMENTAL): 12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period
- Placebo (Type: PLACEBO_COMPARATOR): * 12 weeks Treatment Period: Subjects will receive Placebo~* 4 weeks Down-Titration Period: Subjects will receive Placebo
- BRV 50 mg/day (Type: EXPERIMENTAL): 12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females aged 18 years to less than 55 years~* Body weight 50kg or greater~* Body mass index (BMI) between 18 and 42.0 kg/m2~Exclusion Criteria:~* Evidence of a clinically significant medical condition, disorder or disease~* Evidence of hepatobiliary disease~* Any clinically relevant abnormal laboratory test result~* Evidence or history of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CSL112 (Type: EXPERIMENTAL): Multiple ascending intravenous doses of CSL112
- Placebo (Type: PLACEBO_COMPARATOR): Multiple intravenous infusions of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 20-40 years~* gestational age between 12-30 weeks~* serum HBsAg and HBeAg positivity~* HBV DNA levels \>6log10 copies/mL~* ALT \>1x ULN (40 IU/mL) and \< 10x ULN.~Exclusion Criteria:~* co-infection with hepatitis A, C, D, E or HIV~* evidence of hepatocellular carcinoma; decompensated liver disease or significant renal, cardiovascular, respiratory or neurological co-morbidity~* concurrent treatment with immune-modulators, cytotoxic drugs, or steroids~* clinical signs of threatened miscarriage in early pregnancy~* evidence of fetal deformity by 3-dimensional ultrasound examination~* the biological father of the child had CHB

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): None
- telbivudine (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men with histologically confirmed prostate cancer~* bilateral orchiectomy at least 6 months before randomization or continuous androgen-deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) agonist or antagonist for at least 6 months before randomization~* total testosterone level less than 50 ng/dL,~* hormone refractory (androgen independent) prostate cancer demonstrated during continuous ADT/post-orchiectomy defined as: 3 consecutive prostate-specific antigen (PSA) values with PSA1 \< PSA2 \< PSA3, each PSA value must be separated by at least 2 weeks, PSA2 and PSA3 greater than or equal to 1.0 ng/mL,~* high risk for development of bone metastasis defined as PSA value greater than or equal to 8.0 ng/mL, obtained no more than 3 months before randomization OR PSA doubling time less than or equal to 10.0 months~Exclusion Criteria:~* prior or current evidence of radiographically detectable bone metastasis~* known prior or current evidence of any metastatic involvement of distant organs (lymph node metastases in any region is acceptable)~* prior or current intravenous bisphosphonate administration

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
- Denosumb (Type: EXPERIMENTAL): Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Odiparcil For The Prevention Of Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women must be unable to have children.~* Will have a total knee replacement.~Exclusion Criteria:~* Allergic to any X-ray dye.~* Allergies or reactions to warfarin or coumadin.~* Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).~* On anticoagulation therapy.~* Renal impairment.~* Participated in any clinical trial in the past 30 days.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease~* Hemodialysis~* Hypertension~* Written informed consent~Exclusion Criteria:~* Hypotension of less than 90 mmHg systolic~* High-grade aortic stenosis~* Heart failure of NYHA stage III and IV~* Acute myocardial infarction (within the last 4 weeks)~* Acute heart failure~* Known allergy to the medicament amlodipine or other constituents of the medicament~* Severe disorders of liver function~* Pregnancy and breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Amlodipine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of DAV132 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Normal digestive transit, with usually one daily stool.~* Females participating in the study :~must be either of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or postmenopausal or having a negative pregnancy test and be not breastfeeding at screening, and using abstinence or a double contraception method during the treatment period and for additional period of 2 weeks after the end of investigational treatment.~* Having given and signed the written study informed consent prior to undertaking any study-related procedure.~* Covered by the French Health Insurance system.~Exclusion Criteria:~* Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, bone and joint, muscular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness.~* Contra-indications to fluoroquinolones, or risk factors for adverse events associated to fluoroquinolones.~* Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency should be excluded.~* Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be excluded.~* Contra-indications to DAV132, risk of gastrointestinal obstruction, perforation or haemorrhage, recent digestive tract surgery.~* Fecal colonisation by Clostridium difficile.~* Recent history of hospitalisation (within 3 months prior to inclusion).~* Any antibiotic administration within 3 months before inclusion.~* Any vaccination within the last 28 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
- moxifloxacin + DAV132 (Type: EXPERIMENTAL): Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
- DAV132 (Type: EXPERIMENTAL): DAV132 oral, 7.5g x3/day for 7 days
- Negative control (Type: PLACEBO_COMPARATOR): Negative control: 7.5g x3/day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies~* TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures~* Patient must be willing and able to give written informed consent~* Patient must avoid conception during the trial~Exclusion Criteria:~* Patients who have terminated early from the SHEPHERD or X03-001 studies~* Patients who have terminated early from the TRIUMPH study due to an adverse event~* Female who is pregnant, breast feeding, or intending to conceive during the course of the study~* Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): 600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive Hodgkin lymphoma, Stage IIa or IIb-IV~* Measurable disease of at least 1.5 cm~* Eastern Cooperative Oncology Group performance status \<3~Exclusion Criteria:~* History of another primary malignancy that has not been in remission for at least 3 years~* Known cerebral/meningeal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
- 2 (Type: EXPERIMENTAL): brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study in Patients With Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
1. A diagnosis of ulcerative colitis verified by colonoscopy or barium enema performed within 36 months prior to study entry.~2. Active disease despite ongoing treatment with steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial~* Patients 20 years or older at the time of their consent~* Patients with hypercholesterolemia as defined by any of the following criteria:~  * TC \>= 220 mg/dL;~ * LDL-C \>= 140 mg/dL;~ * Cholesterol-lowering treatment is necessary in accordance with the investigator's judgement when LDL-C \>= 100 mg/dL or TC \>= 180 mg/dL.~* Patients who have been diagnosed with acute coronary syndrome~* Patients with successful percutaneous coronary intervention (PCI) by intravascular ultrasound (IVUS) guidance~* Patients having coronary plaques (\>= 500 µm in thickness or 20% or more in % plaque) at \>= 5 mm from the previously treated area in the same branch of coronary artery~Exclusion Criteria:~* Patients with bypass graft or in-stent restenosis at the site of PCI~* Patients who had received PCI on the lesion in the past where the evaluation of coronary plaque volume is planned~* Patients who had plaques in a non-culprit site and might receive PCI during the treatment period~* Patients receiving lipid-lowering drugs (statins, fibrates, probucol, nicotinic acid or cholesterol absorption inhibitors)~* Patients with familial hypercholesterolemia~* Patients with cardiogenic shock~* Patients receiving cyclosporine~* Patients with any allergy to pitavastatin or atorvastatin~* Patients with hepatobiliary disorders~* Pregnant women, women suspected of being pregnant, or lactating women~* Patients with renal disorders or undergoing dialysis~* Patients who are ineligible in the opinion of the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pitavastatin
- 2 (Type: ACTIVE_COMPARATOR): Atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2, and a body weight ≥ 45 and ≤ 95 kg at the screening visit.~* The subject is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, vital signs, an ECG, and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests at screening.~Exclusion Criteria:~* The subject fulfils the diagnostic criteria for a primary headache disorder, or has a first degree relative with a primary headache disorder, according to the International Headache Society (IHS) International Classification of Headache Disorders 3rd edition (ICHD-3), except tension-type headache.~* The subject has or has had tension-type headache more than once per month on average during the 6 months prior to the screening visit.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + saline (Type: EXPERIMENTAL): Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
- Placebo + VIP and PACAP (Type: EXPERIMENTAL): Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
- Lu AG09222 + VIP and PACAP (Type: EXPERIMENTAL): Lu AG09222, single dose intravenous infusion over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic AMN patients,~* 18-64 years old,~* male and female,~* clinically and biochemically diagnosed;~* females must be obligated heterozygotes or must have gene mutation identified.~Exclusion Criteria:~* Pregnant and lactation in females,~* Cerebral inflammatory disease with cognitive disorder, and/or~* need the help of two walking sticks,~* epilepsy,~* hypersensibility to cysteine related compounds,~* transaminases 2 fold up normal values.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine, lipoic acid and vitamin E (Type: EXPERIMENTAL): Two Dose titration design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : 7-17 years~* Ultrasound (US) or Computed Tomography (CT) confirmed early appendicitis:~  * US: hyperemia, \<1.1 cm in diameter, compressible or non-compressible, no abscess, no fecalith, no phlegmon~ * CT: hyperemia, fat stranding, \<1.1 cm in diameter, no abscess, no fecalith, no phlegmon~* White Blood Cell count \< 18,000~* C-reactive Protein\<4 (if obtained)~* Focal abdominal pain \</= 48 hours prior to receiving antibiotics~Exclusion Criteria:~* Positive urine pregnancy test~* Other significant co-morbidities:~  * cardiovascular disease~ * malignancy~ * pulmonary disease~ * severe developmental delay

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Patient Activation Tool (Type: EXPERIMENTAL): Patients and their caregivers will receive the patient activation tool in addition to standard consultation
- Standard Consultation (Type: NO_INTERVENTION): Patients and their caregivers will receive standard consultation alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete